Fat consumption in western society has increased dramatically throughout the course of the twentieth century. As a consequence, coronary heart disease is now the most common cause of death from middle age onwards in much of the developed world. Yet trials have shown that lipid-lowering drugs can decrease the risk of coronary heart disease and stroke, and increase life expectancy. Using an evidence-based approach this illustrated guide offers practical solutions to the problems encountered by healthcare professionals in the clinical management of hyperlipidaemia.
21 pages matching diagnosis in this book
Results 1-3 of 21
What people are saying - Write a review
We haven't found any reviews in the usual places.
adipose tissue apoB apoB level apoE apolipoprotein atherogenic atheroma atherosclerosis atorvastatin ATPIII Betteridge DJ CHD risk cholesteryl ester chylomicrons circulation clinical trials combined hyperlipidemia coronary disease coronary heart disease decrease dense LDL particles diabetes mellitus diagnosis diet dietary Durrington PN effect elevated apoB enzyme familial fatty acid trapping fibrate Figure foam cells hepatic heterozygotes heterozygous FH homozygous FH hyperlipoproteinemia hypertension hypertriglyceridemia increased insulin resistance LDL cholesterol LDL cholesterol levels LDL particle number LDL receptor lesions levels of LDL lipid lipid-lowering lipoprotein lipase Lipoproteins in Health liver low HDL cholesterol lower Lp(a measurement metabolism mg/dL mmol/L NON-SMOKER SMOKER normal obesity occur oxidation P-blockers pancreatitis particularly phospholipids plasma polygenic hypercholesterolemia primary prevention protein reduced remnants renal risk factors secondary prevention Serum HDL severe hypertriglyceridemia statin statin therapy Study syndrome target tendon xanthomata total cholesterol treatment triglycerides type 2 diabetes type III hyperlipoproteinemia vascular disease VLDL VLDL secretion xanthomata